Citi analyst Yigal Nochomovitz raised the firm’s price target on MacroGenics to $8 from $7 and keeps a Neutral rating on the shares following the Q4 update.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MGNX:
- MacroGenics price target raised to $14 from $12 at H.C. Wainwright
- MacroGenics downgraded to Neutral at Guggenheim on prostate cancer caution
- MacroGenics downgraded to Neutral from Buy at Guggenheim
- MacroGenics Provides Corporate Update and 2022 Financial Results
- MacroGenics expands license agreement with Synaffix
